About GenMark Diagnostics
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: GNMK
- Previous Close: $10.94
- 50 Day Moving Average: $11.71
- 200 Day Moving Average: $11.21
- 52-Week Range: $46,404,000.00 - $4.66
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.61
- P/E Growth: 7.55
- Market Cap: $522.05M
- Outstanding Shares: 46,404,000
- Beta: 0.86
- Net Margins: -98.17%
- Return on Equity: -114.35%
- Return on Assets: -66.62%
Companies Related to GenMark Diagnostics:
- Debt-to-Equity Ratio: 0.30%
- Current Ratio: 3.26%
- Quick Ratio: 3.05%
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
Where is GenMark Diagnostics' stock going? Where will GenMark Diagnostics' stock price be in 2017?
5 analysts have issued 1-year price targets for GenMark Diagnostics' shares. Their predictions range from $7.25 to $17.00. On average, they anticipate GenMark Diagnostics' share price to reach $13.25 in the next twelve months.
When will GenMark Diagnostics announce their earnings?
GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (1/26/2017)
- Needham & Company LLC analysts commented, "On 1/10/17, GNMK preannounced in line 4Q16 revenue and disclosed that it ended 2016 with 55 customer agreements for over 85 ePlex instruments. And on 12/22/16, GNMK announced that it had submitted its 510(k) to the FDA for its ePlex and Respiratory Pathogen Panel; we expect GNMK to launch ePlex in the U.S. in mid-2017. bioMerieux continues to see very strong growth with its FilmArray platform and we think this bodes well for the ePlex launch. We expect the ePlex launch to cause GNMK's revenue growth to accelerate during 2017, and we reiterate our Buy rating." (1/24/2017)
Who owns GenMark Diagnostics stock?
GenMark Diagnostics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Putnam Investments LLC (8.80%), Artisan Partners Limited Partnership (4.07%), State Street Corp (1.58%), FIL Ltd (0.95%) and Thrivent Financial for Lutherans (0.64%). Company insiders that own GenMark Diagnostics stock include Daryl Faulkner, Eric Stier, Hany Massarany, Ingo Chakravarty, Jeffrey Alan Hawkins, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel.
Who sold GenMark Diagnostics stock? Who is selling GenMark Diagnostics stock?
GenMark Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Artisan Partners Limited Partnership, Alyeska Investment Group L.P., Two Sigma Investments LP and Allianz Asset Management AG. Company insiders that have sold GenMark Diagnostics stock in the last year include Eric Stier, Hany Massarany, Ingo Chakravarty, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson and Scott Mendel.
Who bought GenMark Diagnostics stock? Who is buying GenMark Diagnostics stock?
GenMark Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Thrivent Financial for Lutherans, State Street Corp, Russell Investments Group Ltd., Baird Financial Group Inc., A.R.T. Advisors LLC, AQR Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought GenMark Diagnostics stock in the last two years include Daryl Faulkner, Lisa M Giles, Michael Kagnoff and Scott Mendel.
How do I buy GenMark Diagnostics stock?
Shares of GenMark Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of GenMark Diagnostics stock cost?
One share of GenMark Diagnostics stock can currently be purchased for approximately $11.25.